The drug developed by RSS-backed Go Vigyan Anusandhan Kendra had earlier got the US patent as a bio-enhancer with antibiotics and anti-cancer drugs.
The research for the drug brand named 'Kamdhenu Ark' was carried out jointly by the Anusandhan Kendra and National Environmental Engineer Research Institute NEERI.
The research found that Re-distilled Cow Urine Distillate (RCUD) was useful for protecting and repairing DNA from oxidative damage, Chakraborty and Sunil Mansinghka of Kendra told reporters yesterday.
Oxidative DNA damage is a leading cause of ageing, cancer and other diseases.
RCUD works against genotoxicity, a harmful action on a cell's genetic material, they said, adding research has strengthened the efficacy of 'Kamdhenu Ark' as an anti-cancer drug.
The research was carried out on three patients, two of them having throat and uterus cancer,
FIELD OF THE INVENTION
The invention relates to an absolutely novel use of cow urine distillate as activity enhancer and availability facilitator for bioactive molecules including anti-infective and anti-cancer agents. The molecules which express any activity in form of either inhibiting or promoting a biological function have been referred in this invention as bioactive molecule e.g. antibiotics, drugs, nutraceuticals, cardiovascular, hepatoprotective, neuro-tonics etc. The present invention has direct implication in drastically reducing the dosage of antibiotics, drugs and anti-cancer agent while increasing the efficiency of absorption of bioactive molecules.
Name of disease | No. of patients | Average age of patient | Average duration of disease | Average Time of relief |
Ovarian Tumour | 10 | 61 years | 2 years | 2.5 months |
Benign Prostatic Hypertrophy | 20 | 61.5 years | 1.5 years | 3.8 months |
Renal Cell Carcinoma | 10 | 68 years | 2 years | 2.8 months |
Breast Cancer | 50 | 45 years | 3.66 years | 3.5 months |
CLL | 20 | 60.5 years | 3.41 years | 2 months |
Tubercullar Lymphadenopathy | 10 | 34 years | 10 years | 1.9 months |
Cervical Cancer | 10 | 56 years | 3 years | 3.2 months |
Uterine Fibroid | 20 | 41.5 years | 2 years | 2.2 months |
Prostate Cancer | 10 | 62 years | 1 year | 3.1 months |
Urinary Bladder Cancer | 10 | 55 years | 1 year | 3.5 months |
Neurofibroma | 10 | 39 years | 25 years | 1.8 months |
Throat Cancer | 20 | 64 years | 0.54 year | 3.4 months |
Sub Mucous Fibrosis | 30 | 35.66 years | 4.33 years | 2.4 months |
Oral Cancer | 20 | 53.3 years | 3 years | 3.6 months |
Acute lymphoblastic Cancer | 15 | 35 years | 3 years | 2.3 months |
Cancer (Benign or malignant) | 250 | 50.76 years | 3.84 years | 2.8 months |
The above study was based on the symptomatic relief found to the patient undergoing our treatment. The symptomatic relief signifies the improvement in physical conditions like low diet, difficulty in swallowing, constipation, vomiting, sever pain and other problems. Further various researches have been done and going on which signifies its role as follows:
(US Patent #6410059): Cow Urine in a specific amount is scientifically proven to enhance the anti-microbial effects of antibiotic and antifungal agents. The invention relates to a novel use of cow urine as activity enhancer and availability facilitator for bioactive molecules, including anti-infective agents. The invention has direct implication in drastically reducing the dosage of antibiotics, drugs and anti-infective agent while increasing the efficiency of absorption of bio-active molecules, thereby reducing the cost of treatment and also the side-effects due to toxicity.
(US Patents #6896907, #7235262): Use of bioactive fraction from cowurine (`go-mutra`) as a bio-enhancer of anti-infective, anti-cancer agents and nutrients. The invention relates to a novel pharmaceutical composition comprising an effective amount of bio-active fraction from cow urine as a bioavailability facilitator and pharmaceutically acceptable additives selected from anticancer compounds, antibiotics, drugs, therapeutic and nutraceutic agents, ions and similar molecules which are targeted to the living systems.
Hence it heps in reducing the growth of cancer cells, improving the quality of life and life expectancy
of the patient.
(US Patent #6410059): Cow Urine in a specific amount is scientifically proven to enhance the anti-microbial effects of antibiotic and antifungal agents. The invention relates to a novel use of cow urine as activity enhancer and availability facilitator for bioactive molecules, including anti-infective agents. The invention has direct implication in drastically reducing the dosage of antibiotics, drugs and anti-infective agent while increasing the efficiency of absorption of bio-active molecules, thereby reducing the cost of treatment and also the side-effects due to toxicity.
(US Patents #6896907, #7235262): Use of bioactive fraction from cowurine (`go-mutra`) as a bio-enhancer of anti-infective, anti-cancer agents and nutrients. The invention relates to a novel pharmaceutical composition comprising an effective amount of bio-active fraction from cow urine as a bioavailability facilitator and pharmaceutically acceptable additives selected from anticancer compounds, antibiotics, drugs, therapeutic and nutraceutic agents, ions and similar molecules which are targeted to the living systems.
Hence it heps in reducing the growth of cancer cells, improving the quality of life and life expectancy
of the patient.
SOURCES-
CLICK HERE
CLICK HERE
COW URINE RESEACH